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PERSPECTIVE
Dimethyltryptamine (DMT): a 
biochemical Swiss Army knife 
in neuroinflammation and 
neuroprotection? 
The inflammatory theory of many neuropsychiatric illnesses 
has become an emerging trend in modern medicine. Various 
immune mechanisms – mainly via the activity of microglia 
– may contribute to the etiology and symptomatology of 
diseases, such as schizophrenia, bipolar disorder, depression, 
or Alzheimer’s disease (Deleidi et al., 2015; Khandaker et al., 
2015). Unwanted and excess inflammation is most typically 
the result of dysregulated innate immune responses. Recog-
nition of self-derived damage-associated molecular patterns 
(DAMPs) or pathogen-associated molecular pattern mole-
cules (PAMPs) is usually leading to the activation of tissue 
resident immune cells including macrophages (microglia) 
and dendritic cells. They act as ‘gatekeepers’ continuously 
monitoring the tissue microenvironment for potential ’dan-
ger signals’ by means of their pattern recognition receptors, 
such as Toll-like receptors or RIG-I-like receptors. Once a 
DAMP or PAMP has been recognized by a pattern recogni-
tion receptor various downstream signaling pathways are 
initiated, which eventually leads to the secretion of inflam-
matory cytokines and many other soluble factors important 
in the elimination of e.g. invading microbes. Pattern recogni-
tion receptors couple to nuclear factor kappaB (NF-κB), the 
master transcription regulator of inflammatory cytokines 
(e.g., IL-1β, IL-6, TNFα) and chemokines (e.g., IL-8/CXCL8) 
(Szabo and Rajnavolgyi, 2013). Macrophages and dendritic 
cells are also capable of antigen-presentation so they can 
initiate adaptive immune responses by priming naive T-cells. 
During inflammation of the central nervous system, polar-
ization towards the T helper 1 and 17 (Th1, Th17) subsets is 
especially important as these T cells play a major role in the 
development of chronic inflammation and brain tissue dam-
age in infectious diseases and autoimmunity (Kothur et al., 
2016).
It has been known for decades that immunomodulation 
through serotonin/5-hydroxytryptamine receptors (5-HTRs) 
has the potential to regulate inflammation and prevent dam-
age of the nervous tissue (Shajib and Khan, 2015). Recently 
another receptor has been added to the greater picture: the 
orphan receptor sigma-1 (Sig-1R). 5-HTRs and Sig-1R have 
been shown to be expressed ubiquitously in higher verte-
brate tissues and mediate various processes, including the 
regulation of cognition and behavior, body temperature, as 
well as immune functions (Szabo, 2015). Both 5-HTRs and 
the Sig-1R use G protein-coupled (GPCR) pathways thereby 
modulating a plethora of cellular functions, such as cyto-
kine/neurotransmitter release, proliferation, differentiation, 
and apoptosis. The molecular chaperone Sig-1R is located at 
the endoplasmic reticulum-mitochondrion interface and has 
an important role in the fine-tuning of cellular metabolism 
and energetics under stressful conditions (Hayashi, 2015). 
At the MAM, Sig-1Rs are involved in the regulation and 
mobilization of calcium from endoplasmic reticulum stores. 
Neuroprotection by Sig-1R activation can be attained by 
preventing elevations of intracellular calcium-mediated cell 
death signaling (Ruscher and Wieloch, 2015). Based on its 
central localization and function, pivotal physiological activ-
ities of the Sig-1R have been described such as indispensable 
role in neuronal differentiation, neuronal signaling, cellular 
survival in hypoxia, resistance against oxidative stress, and 
mitigating unfolded protein response (Pal et al., 2012).
Tryptaminergic trace amines (e.g., N,N-dimethyltrypt-
amine; DMT) as well as neurosteroids (e.g., dehydroepi-
androsterone) are endogenous ligands of the Sig-1R (Fon-
tanilla et al., 2009). Tryptamines are naturally occurring 
monoamine alkaloids sharing a common biochemical – 
tryptamine – backbone. DMT was shown to be endogenous-
ly present in the human brain and in other tissues of the 
body, however the exact physiological role of this tryptamine 
has not been identified yet (Frecska et al., 2013). It has been 
shown that, besides its affinity for the Sig-1R, DMT also 
acts as an agonist at numerous serotonin receptors, such as 
5-HT1A, 5-HT2A, and 5-HT2C (Keiser et al., 2009; Ray, 2010). 
This wide-spectrum agonist activity may allow DMT to 
modulate several physiological processes and regulate in-
flammation through the Sig-1R and 5-HTRs. Indeed, DMT 
has been found to modulate immune responses through the 
Sig-1R under various conditions. These include the suppres-
sion of inflammation by blocking inflammatory cytokine 
and chemokine release of dendritic cells, as well as inhibiting 
the activation of Th1 and Th17 subsets (Szabo et al., 2014). 
The biochemical background of this extensive ability lies in 
the possible cross-talk of the GPCR-coupled downstream 
signaling of 5-HTRs/Sig-1R and other inflammatory path-
ways in immune cells, as well as the fine-tuning of cytokine 
feedback loops in peripheral tissues. Thus, in neuroinflam-
mation, two major scenarios are possible: i) the modulation 
of cytokine production by brain resident microglia that 
implies a negative feedback regulation of inflammation via 
the induction of the release of anti-inflammatory IL-10 and 
TGFβ occurring subsequent of both 5-HTR and Sig-1R ac-
tivation; ii) the direct/indirect control of NF-κB signaling 
and possibly other pathways (e.g., MAPKs) involved in in-
flammation through intracellular kinases, adaptor proteins, 
etc (reviewed by Szabo, 2015). This way, the activation of 
5-HTRs and Sig-1R may also interfere with the chemokine, 
inflammatory cytokine signaling of immune cells through 
intracellular mechanisms. Most of the receptors that are 
involved in psychedelic effects belong to the GPCR family 
or interact with GPCRs (Rogers, 2012). The role of 5-HTR/
Sig-1R GPCR-coupled signals in the intracellular regulation 
and orchestration of NF-κB and MAPK pathways may be of 
particular importance regarding the complex neuroimmuno-
logical effects of DMT. Specific stimulation of the 5HTR1 and 
5HTR2 receptor subtypes results in the activation of NF-κB 
and several MAPKs in many cell types including immune cells 
(Szabo, 2015). This coordinated cross-talk between MAPKs 
(including p38, MEKK1, ERK, and PI3K/Akt) and NF-κB 
leads to an intricate regulation of inflammatory responses 
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by the spatio-temporal adjustment of cytokine release. The 
inhibitory or stimulatory effect of GPCR activation on NF-
κB and MAPK pathway kinetics is largely depending on the 
G-proteins that are involved. DMT, acting through mainly 
5HTR1, 5HTR2, and Sig-1R receptors subtypes, regulates NF-
κB and MAPKs via Gα (Gi and Gq families), and Gβγ pro-
teins (Raymond et al., 2011). The Gq family of α subunits 
couple a large number of GPCRs to PLC-β, and many of 
these have been shown to activate NF-κB. This mechanism 
is based on the activity of the IκB kinases IKKα and IKKβ, as 
well as the PI3K pathway involving the serine/threonine pro-
tein kinase Akt (Xie et al., 2000). The PLC-β-IP3 axis-me-
diated release of calcium from intracellular stores results in 
the activation of the second messenger conventional protein 
kinase C (PKC). This calcium signal can also be attenuated 
by the activation of Sig-1R (Fontanilla et al., 2009), thus this 
receptor may couple to MAPK and NF-κB signaling and 
regulate inflammation (as well as apoptotic processes initi-
ated by prolonged unfolded protein response) through this 
mechanism, as well. The above outlined picture suggests a 
direct control of NF-κB transcriptional regulation of chemo-
kines, pro-inflammatory and anti-inflammatory cytokines, 
which may render DMT as a potentially useful therapeutic 
tool in a broad range of chronic inflammatory and autoim-
mune diseases, and pathological conditions connected to in-
creased unfolded protein responseincluding but not restrict-
ed torheumatoid arthritis, multiple sclerosis, amyotrophic 
lateral sclerosis (ALS), Alzheimer’s and Parkinson’s disease, 
etc. However, the powerful hallucinogenic property of DMT 
poses an important problem that must be addressed in fu-
ture drug design.
Protective and neuroregenerative effects of Sig-1R agonists 
have been reported in several in vitro and in vivo studies. The 
selective Sig-1R agonists 2-(4-morpholinethyl)1 phenylcy-
clohexanecarboxylate (PRE084) and cutamesine have been 
shown to strongly promote neuroprotective mechanisms and 
significantly increase neuronal cell survival and regeneration 
under various conditions, such as traumas, autoimmunity, 
and neurodegenerative disorders (Penas et al., 2011; Yamashita 
et al., 2015). Specific Sig-1R stimulation has also been found 
to greatly increase the levels of the glial cell-derived neuro-
trophic factor GDNF that promotes neuronal cell survival and 
differentiation (Penas et al., 2011). The neuroregenerative po-
tential of DMT through the Sig-1R has been suggested earlier 
as multiple biochemical and physiological mechanisms exist, 
which facilitate the transportation and binding of DMT to the 
Sig-1R in the mammalian brain (Frecska et al., 2013). Thus 
DMT – as a natural, endogenous agonist at both the Sig-1R 
and 5-HTRs – is hypothesized to be an unique, many-faced 
pharmacological entity, which has many important roles in 
the immunoregulatory processes of peripheral and brain tis-
sues, as well as involved in the promotion and induction of 
neuroregeneration in the mammalian nervous system.
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